CymaBay Therapeutics Inc. (CBAY)
CBAY moved a median of +0.02% 30 minutes after news, and +0.09% by the close. How CBAY actually reacts to news — the realized, point-in-time move the market made, measured across 166 labeled events over the last three years with zero look-ahead.
CBAY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 125 |
| 30-min | +0.02% | 52% | 125 |
| 60-min | +0.05% | 56% | 125 |
| to close | +0.09% | 54% | 125 |
| Middle 50% of CBAY reactions | -0.30% to +0.79% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 166 |
Half of all CymaBay Therapeutics Inc. news events land between -0.30% and +0.79% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CBAY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 24 | +0.16% | 67% | 0.00% |
| Rating reiterations | 19 | +0.16% | 58% | 0.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CBAY ranks against every other measured name →
That’s how CBAY usually reacts — get an email when it moves on news →Email me when CBAY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CBAY's baseline. Nothing else.
Recent CBAY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G CymaBay Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT CymaBay Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K CymaBay Therapeutics, For: Mar 22 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM CymaBay Therapeutics, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR CymaBay Therapeutics, | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS CymaBay Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K CymaBay Therapeutics, For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.03% | |
| CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis | Press release | GlobeNewswire | +0.00% | -0.19% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL) | Press release | GlobeNewswire | +0.02% | -0.12% | |
| SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI | Press release | PR Newswire | -0.11% | +0.00% | |
| CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.15% | -0.28% | |
| Form 10-K CymaBay Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.15% | -0.28% | |
| SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE | Press release | GlobeNewswire | +0.03% | +0.15% | |
| The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis | Press release | PR Newswire | +0.00% | -0.06% | |
| CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.12% | +0.09% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB) | Press release | GlobeNewswire | +0.09% | +0.39% | |
| CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.17% | +0.88% | |
| CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis | Press release | PR Newswire | +0.02% | +0.81% | |
| Form 8-K CymaBay Therapeutics, For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +0.81% | |
| INVESTIGATION ALERT: Halper Sadeh LLC Investigates FANG, WISH, CBAY | Press release | PR Newswire | +0.02% | +0.28% | |
| CymaBay Therapeutics to Participate in Upcoming Investment Conferences | Press release | GlobeNewswire | +1.51% | -1.05% | |
| Form 8-K CymaBay Therapeutics, For: Jan 24 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | +3.44% | |
| CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.67% | +1.18% | |
| New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar | Press release | PR Newswire | +0.46% | -3.53% | |
| CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024 | Press release | GlobeNewswire | -0.83% | +1.11% | |
| Form 8-K CymaBay Therapeutics, For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +3.64% | |
| CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.38% | -1.61% | |
| CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis | Press release | PR Newswire | +0.39% | +1.33% | |
| Form 8-K CymaBay Therapeutics, For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -2.13% | -0.87% | |
| CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.48% | +1.63% | |
| CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting® | Press release | PR Newswire | -2.44% | +5.50% | |
| CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.80% | -4.27% | |
| Form 10-Q CymaBay Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.80% | -4.27% | |
| CymaBay Therapeutics to Present at Upcoming Investment Conferences | Press release | GlobeNewswire | -0.96% | -1.50% | |
| CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis | Press release | GlobeNewswire | -0.12% | +0.00% | |
| CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023 | Press release | GlobeNewswire | -0.12% | +0.00% | |
| CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023 | Press release | GlobeNewswire | +0.53% | +3.87% | |
| Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis | Press release | GlobeNewswire | -0.59% | +8.09% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CBAY section they belong to.
Where else CBAY is measured.
CBAY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | 167 | -0.32% | 42% |
| Boundless Bio, Inc. (BOLD) | 166 | -0.48% | 44% |
| Innoviva, Inc. (INVA) | 166 | +0.10% | 54% |
| MediWound Ltd. - Ordinary Shares (MDWD) | 166 | +0.11% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CymaBay Therapeutics Inc.'s median reaction calculated?
Every labeled CBAY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 166 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of CBAY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CBAY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.